Mucormycosis In COVID-19: Does It Even Exist: Mucormycosis in COVID-19: Does it Even Exist

Muhammad Wajad  Munir; Abdur  Rehman; Sheharyar  Raashid; Quratulain  Tanveer; Hassan  Mumtaz

doi:10.54393/pbmj.v5i1.296

Authors

Muhammad Wajad Munir Al-Nafees Medical College and Hospital, Islamabad
Abdur Rehman Isolation Hospital and Infections Treatment Centre (IHITC), Islamabad, Pakistan
Sheharyar Raashid Isolation Hospital and Infections Treatment Centre (IHITC), Islamabad, Pakistan
Quratulain Tanveer Isolation Hospital and Infections Treatment Centre (IHITC), Islamabad, Pakistan
Hassan Mumtaz Maroof International Hospital, Islamabad, Pakistan

DOI:

https://doi.org/10.54393/pbmj.v5i1.296

Keywords:

COVID-19, Mucormycosis, Post-op care, Palliative Care

Abstract

The WHO named the COVID-19 epidemic, which was caused by the SARS-CoV-2 coronavirus, a global pandemic on March 11, 2020. Doctors noted an increase in incidences of Mucormycosis towards the beginning of May 2020. Case Presentation: A 48-year-old female patient complained of fever, body aches, vomiting, abdominal pain, diarrhea and no weakness or numbness. A chest x-ray revealed bilateral pneumonia. Treatment with steroids, antibiotics, remdesivir and anticoagulation was initiated. Patient was diagnosed with sinusitis with right orbital cellulitis, moderated proptosis and frank osseous erosions. Concomitantly patient developed a scrapable black eschar on the upper palate. Patient further underwent FESS surgery of the maxillary sinuses of both sides. Patient was sent home after an appreciable recovery and put on a close follow up list. Conclusion: Diabetes mellitus sufferers are particularly susceptible to this fungus's deadly effects. For individuals with mucromycosis, swift and precise diagnostic facilities, medical aid and a speedy yet coordinated response are all recommended.

References

Cucinotta D, Vanelli M, 2020. WHO declares COVID-19 a pandemic. Acta Biomed 91: 157–160.

Worldometer , 2021. Live Update COVID, 170,736,293 Cases and 3,550,650 Deaths from the Coronavirus. Available at:https://www.worldometers.info/coronavirus/. Accessed May 30, 2021

Gandra S, Ram S, Levitz SM, 2021. The “Black Fungus” in India: the emerging syndemic of COVID-19–associated mucormycosis. Ann Intern Med (E-pub ahead of print).

Shakir M, Maan MHA, Waheed S. BMJ Case Rep 2021;14:e245343. doi:10.1136/bcr-2021- 245343

Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020;71:2459–68.

Nasir N, Farooqi J, Mahmood SF, et al. COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: an observational study from Pakistan. Mycoses 2020;63:766–70.

White PL, Dhillon R, Cordey A, et al. A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. Clin Infect Dis 2020. doi:10.1093/cid/ ciaa1298. [Epub ahead of print: 29 Aug 2020].

Zaidi SJA, Maqsood S. Can Dentists Prevent Black Fungus in Post-COVID-19 Patients?. J Coll Physicians Surg Pak 2021; 31(Supp1): S155-S157.

S Afzal, M Nasir. Aspergillosis and Mucormycosis in COVID-19 Patients; a Systematic Review and Meta-analysis. medRxiv 2021.08.01.21261458; doi: https://doi.org/10.1101/2021.08.01.21261458

Rabia Kanwar et al (2021). Emergence of Mucormycosis: A Therapeutic Challenge for COVID-19 in Pakistan. Saudi J Pathol Microbiol, 6(10): 363-368.